Cytokinetics Inc CYTK
News
Cytokinetics Announces Closing of Public Offering of Common Stock
Cytokinetics Announces Pricing of Public Offering of Common Stock
Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
Cytokinetics Announces Proposed Public Offering of Common Stock
Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
Cytokinetics Hosts Muscle Biology-Focused Research Symposium: Contemporary Landscapes in Muscle Biology
Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2024
Cytokinetics Announces Additional Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress
Cytokinetics Announces Primary Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress and Published in the New England Journal of Medicine
Cytokinetics Reports First Quarter 2024 Financial Results
Cytokinetics Announces Start of CEDAR-HCM, a Clinical Trial of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Cytokinetics Announces Topline Data From Phase 1 Clinical Study of CK-4021586
Cytokinetics to Hold Annual Meeting of Stockholders
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cytokinetics to Host Investor Event and Conference Call to Discuss the Primary Results From SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
Cytokinetics to Announce First Quarter Results on May 8, 2024
Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73ʳᵈ Annual Scientific Session
Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73ʳᵈ Annual Scientific Session